PeptideStack
5.2kquestions
20kanswers
220users

Does splitting a 2.5 mg weekly dose of oral semaglutide across two administrations change anything?

Asked 9 Apr 2026Modified 4 months agoViewed 6.3k times
19

The case in front of me: 2.5 mg · oral semaglutide.

This is one of those things that everyone repeats and nobody derives.

This matters practically, not just academically, because it changes what I would do next.

Why does this happen, and what would falsify the usual explanation?

split-dosing
split-dosing

Dividing a weekly dose across more than one administration. Questions here concern the pharmacokinetic rationale, whether the peak-to-trough ratio…

39 questionsdosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questionsglp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

175 questions
shareeditfollowflag
RP
askedretest_please13k289 Apr 2026
2This is the answer I was looking for three months ago. – unit_math 9 months ago
3The arithmetic checks out. I ran the same numbers and got the same result. – micron22 30 days ago
add a comment

No answers yet

This question has not been answered. It has been viewed 6.3k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.